Immunovant, Inc. (IMVT) is focusing on its next-generation anti-FcRn antibody, IMVT-1402 (imeroprubart), which is designed to treat autoimmune diseases associated with pathogenic IgG autoantibodies. The company has shifted its bullish outlook from batoclimab to IMVT-1402, which has demonstrated encouraging efficacy in treating difficult-to-treat rheumatoid arthritis (RA). Notably, by week 16, 72.7% of patients in the trial reported good responses to the treatment. Additionally, Immunovant boasts a solid balance sheet, with management confident in their financial runway leading up to future clinical readouts. Analysts suggest that IMVT-1402's broad potential across several indications could establish it as a franchise asset, although further data is needed to confirm this. Given the promising results and the company’s financial stability, Immunovant is viewed as a viable speculative 'Buy', despite the inherent risks associated with clinical trials.